© 2023 MJH Life Sciences™ and Contemporary OB/GYN. All rights reserved.
In case you missed it: Feb. 21 to Feb. 25
Check out the week’s top stories.
HHS awards nearly $55 million to increase access to underserved populations
Twenty-nine HRSA-funded health centers to receive a boost in technology to improve outcomes.
AUGS executive summary: Postoperative opioid prescribing after female pelvic medicine and reconstructive surgery
The American Urogynecologic Society (AUGS) published an executive summary on postoperative opioid prescribing after female pelvic medicine and reconstructive surgery.
Identifying the optimal gestational weight gain for infant health
Gone are the days of little guidance for weight gain during pregnancy, but determining the best weight range has been elusive. A new study provides some helpful advice.
Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
What physicians need to know about the civil rights complaint process
Don’t dread a call from OCR investigators. They are here to help physicians and other providers avoid astronomical monetary penalties.